VEGF inhibitor

Eylea HD
Pharma

Regeneron's Eylea franchise stumbles on several fronts in Q1

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker.
Fraiser Kansteiner Apr 29, 2025 2:50pm
eye anatomy

Clearside's CLS-AX excels in phase 2b trial, set for phase 3

Oct 9, 2024 11:47am
boxing punch blow hit punching bag fight

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study

Sep 8, 2024 11:30am
Barr

Merck CMO talks Akeso, Summit's Keytruda head-to-head win

Jun 3, 2024 12:00pm
A gavel in the foreground with the scale of justice in the background

Appeals court backs Regeneron's antitrust suit against Novartis

Mar 19, 2024 10:40am
FDA

FDA rejects Outlook's Avastin reformulation for eye disease

Aug 30, 2023 11:30am